EORTC-90091-10093-NOCI-BCG

TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)
Study documentation
Trial StatusClosed for recruitment
DatesDate of activation: 26-Apr-13
Date Step1 close: 03-Oct-16
Data management at EORTCFull
Phase2
Randomized trial
Type-
Targeted Sample sizeEORTC Groups: 25 - All Groups: 174
Number of steps3
DrugTrastuzumab
Study StaffMichail Ignatiadis
Study Coordinator - Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels
Saskia Litiere
Statistician - EORTC Headquarters, Brussels
Tiana Raveloarivahy
Data Manager - EORTC Headquarters, Brussels
tiana.raveloarivahy (at) eortc.be - +32 27741622
Kim Aalders
Coordinating Physician - EORTC Headquarters, Brussels
Konstantinos Tryfonidis
Coordinating Physician - EORTC Headquarters, Brussels
Melanie Beauvois
Project Manager - EORTC Headquarters, Brussels
melanie.beauvois (at) eortc.be - +32 27741687
Christine de Balincourt
Clinical Research Associate - EORTC Headquarters, Brussels
christine.debalincourt (at) eortc.be
Zineb Wadid
Clinical Research Associate - EORTC Headquarters, Brussels
zineb.wadid (at) eortc.be
Type of cancerBreast
Participating GroupsEORTC Network of Core Institutions(Coordinating Group)
EORTC Breast Cancer Group
SUCCESS
UNICANCER
Participating centers
Protocol summaryClinicalTrials.gov
NCT numberNCT01548677
EudraCT2009-017485-23